Vanda Pharmaceuticals Inc.
VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment ofā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.33
Price-0.86%
-$0.05
1Y
Price
Market Cap
$320.739m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-86.8%
EBITDA Margin-93.9%
Net Profit Margin-97.5%
Free Cash Flow Margin-86.8%
EBITDA Margin-93.9%
Net Profit Margin-97.5%
Free Cash Flow MarginRevenue
$217.782m
+0.8%
1y CAGR+4.2%
3y CAGR-2.9%
5y CAGREarnings
-$239.547m
-8.6%
1y CAGR-642.8%
3y CAGR-497.1%
5y CAGREPS
-$4.05
-8.3%
1y CAGR-659.0%
3y CAGR-510.2%
5y CAGRBook Value
$280.765m
$433.525m
Assets$152.760m
Liabilities$13.073m
DebtDebt to Assets
3.0%
-0.1x
Debt to EBITDAFree Cash Flow
-$127.296m
-15.3%
1y CAGR-275.3%
3y CAGR-221.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company